U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H32F6N4O
Molecular Weight 578.5928
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NETUPITANT

SMILES

Cc1ccccc1-c2cc(ncc2N(C)C(=O)C(C)(C)c3cc(cc(c3)C(F)(F)F)C(F)(F)F)N4CCN(C)CC4

InChI

InChIKey=WAXQNWCZJDTGBU-UHFFFAOYSA-N
InChI=1S/C30H32F6N4O/c1-19-8-6-7-9-23(19)24-17-26(40-12-10-38(4)11-13-40)37-18-25(24)39(5)27(41)28(2,3)20-14-21(29(31,32)33)16-22(15-20)30(34,35)36/h6-9,14-18H,10-13H2,1-5H3

HIDE SMILES / InChI

Molecular Formula C30H32F6N4O
Molecular Weight 578.5928
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/?term=16332435; http://www.ncbi.nlm.nih.gov/pubmed/?term=24631949

Fosnetupitant is a prodrug form of netupitant. Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Upon intravenous administration, fosnetupitant is converted by phosphatases to its active form. It competitively binds to and blocks the activity of NK-1 receptors in the central nervous system, by inhibiting binding of substance P (SP) to NK-1 receptors. This prevents delayed emesis, which is associated with SP secretion. AKYNZEO® is a combination of palonosetron, a serotonin-3 receptor antagonist, and netupitant (capsules for oral use) or fosnetupitant (injections for intravenous use). AKYNZEO® for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

CNS Activity

Curator's Comment:: Studies in rodents suggest that Netupitant behaves as a brain penetrant, orally active

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.95 nM [Ki]
Target ID: P25103
Gene ID: 6869.0
Gene Symbol: TACR1
Target Organism: Homo sapiens (Human)
0.95 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
AKYNZEO

Approved Use

AKYNZEO for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.

Launch Date

1.52400966E12
Preventing
Akynzeo

Approved Use

To treat nausea and vomiting in patients undergoing cancer chemotherapy

Launch Date

1.41289914E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
434 ng/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NETUPITANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
14401 ng × h/mL
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NETUPITANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
96 h
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NETUPITANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
0.5%
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
NETUPITANT plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day single, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: single
Dose: 600 mg, 1 times / day
Co-administed with::
palonosetron(1.5 mg; single dose)
Sources:
healthy, mean age 32.8 years
n = 49
Health Status: healthy
Age Group: mean age 32.8 years
Sex: M+F
Population Size: 49
Sources:
Other AEs: Palpitations, Constipation...
Other AEs:
Palpitations (2%)
Constipation (4.1%)
Pain in extremity (2%)
Dizziness (2%)
Headache (10.2%)
Somnolence (2%)
Anxiety (2%)
Euphoric mood (2%)
Sources:
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Disc. AE: Neutropenia, Neoplasm progression...
AEs leading to
discontinuation/dose reduction:
Neutropenia (0.5%)
Neoplasm progression (0.5%)
Neoplasm malignant (0.4%)
Febrile neutropenia (0.2%)
Leukopenia (0.2%)
Thrombocytopenia (0.1%)
Peritonitis (0.1%)
Troponin increased (0.1%)
Stomatitis (0.2%)
ALT increased (0.2%)
Platelet count decreased (0.2%)
Angina pectoris (0.1%)
Myocardial ischaemia (0.1%)
Creatinine renal clearance decreased (0.1%)
Sources:
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Other AEs: Febrile neutropenia, Neutropenia...
Other AEs:
Febrile neutropenia (1.5%)
Neutropenia (1%)
Vomiting (0.6%)
Anaemia (0.5%)
Leukopenia (0.3%)
Pneumonia (0.4%)
Urinary tract infection (0.3%)
Pulmonary embolism (0.2%)
Cardiopulmonary failure (0.3%)
Stomatitis (0.3%)
Asthenia (0.2%)
Neoplasm malignant (0.2%)
Nausea (0.1%)
Peritonitis (0.1%)
Renal failure (0.1%)
Abdominal pain (0.2%)
Diarrhoea (0.2%)
Multi-organ failure (0.2%)
Pyrexia (0.2%)
Femur fracture (0.2%)
Neoplasm progression (0.2%)
Metrorrhagia (0.2%)
Haemoptysis (0.2%)
Thrombocytopenia (0.1%)
Electrolyte imbalance (0.1%)
Convulsion (0.1%)
Deep vein thrombosis (0.1%)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
Other AEs: ALT increased, AST increased...
Other AEs:
ALT increased (grade 3, 1.3%)
AST increased (grade 3, 0.8%)
AST increased (grade 4, 0.1%)
Alkaline phosphatase increased (grade 3, 0.4%)
Hyperglycemia (grade 3, 7.8%)
Hyperglycemia (grade 4, 0.6%)
Hypokalemia (grade 3, 1.4%)
Hypokalemia (grade 4, 0.4%)
Hyponatremia (grade 3, 4.9%)
Hyponatremia (grade 4, 0.6%)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
AEs

AEs

AESignificanceDosePopulation
Headache 10.2%
600 mg 1 times / day single, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: single
Dose: 600 mg, 1 times / day
Co-administed with::
palonosetron(1.5 mg; single dose)
Sources:
healthy, mean age 32.8 years
n = 49
Health Status: healthy
Age Group: mean age 32.8 years
Sex: M+F
Population Size: 49
Sources:
Anxiety 2%
600 mg 1 times / day single, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: single
Dose: 600 mg, 1 times / day
Co-administed with::
palonosetron(1.5 mg; single dose)
Sources:
healthy, mean age 32.8 years
n = 49
Health Status: healthy
Age Group: mean age 32.8 years
Sex: M+F
Population Size: 49
Sources:
Dizziness 2%
600 mg 1 times / day single, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: single
Dose: 600 mg, 1 times / day
Co-administed with::
palonosetron(1.5 mg; single dose)
Sources:
healthy, mean age 32.8 years
n = 49
Health Status: healthy
Age Group: mean age 32.8 years
Sex: M+F
Population Size: 49
Sources:
Euphoric mood 2%
600 mg 1 times / day single, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: single
Dose: 600 mg, 1 times / day
Co-administed with::
palonosetron(1.5 mg; single dose)
Sources:
healthy, mean age 32.8 years
n = 49
Health Status: healthy
Age Group: mean age 32.8 years
Sex: M+F
Population Size: 49
Sources:
Pain in extremity 2%
600 mg 1 times / day single, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: single
Dose: 600 mg, 1 times / day
Co-administed with::
palonosetron(1.5 mg; single dose)
Sources:
healthy, mean age 32.8 years
n = 49
Health Status: healthy
Age Group: mean age 32.8 years
Sex: M+F
Population Size: 49
Sources:
Palpitations 2%
600 mg 1 times / day single, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: single
Dose: 600 mg, 1 times / day
Co-administed with::
palonosetron(1.5 mg; single dose)
Sources:
healthy, mean age 32.8 years
n = 49
Health Status: healthy
Age Group: mean age 32.8 years
Sex: M+F
Population Size: 49
Sources:
Somnolence 2%
600 mg 1 times / day single, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: single
Dose: 600 mg, 1 times / day
Co-administed with::
palonosetron(1.5 mg; single dose)
Sources:
healthy, mean age 32.8 years
n = 49
Health Status: healthy
Age Group: mean age 32.8 years
Sex: M+F
Population Size: 49
Sources:
Constipation 4.1%
600 mg 1 times / day single, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: single
Dose: 600 mg, 1 times / day
Co-administed with::
palonosetron(1.5 mg; single dose)
Sources:
healthy, mean age 32.8 years
n = 49
Health Status: healthy
Age Group: mean age 32.8 years
Sex: M+F
Population Size: 49
Sources:
Angina pectoris 0.1%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Creatinine renal clearance decreased 0.1%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Myocardial ischaemia 0.1%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Peritonitis 0.1%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Thrombocytopenia 0.1%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Troponin increased 0.1%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
ALT increased 0.2%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Febrile neutropenia 0.2%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Leukopenia 0.2%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Platelet count decreased 0.2%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Stomatitis 0.2%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Neoplasm malignant 0.4%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Neoplasm progression 0.5%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Neutropenia 0.5%
Disc. AE
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources:
unhealthy, median age 55 years
n = 1033
Convulsion 0.1%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Deep vein thrombosis 0.1%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Electrolyte imbalance 0.1%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Nausea 0.1%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Peritonitis 0.1%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Renal failure 0.1%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Thrombocytopenia 0.1%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Abdominal pain 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Asthenia 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Diarrhoea 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Femur fracture 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Haemoptysis 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Metrorrhagia 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Multi-organ failure 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Neoplasm malignant 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Neoplasm progression 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Pulmonary embolism 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Pyrexia 0.2%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Cardiopulmonary failure 0.3%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Leukopenia 0.3%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Stomatitis 0.3%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Urinary tract infection 0.3%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Pneumonia 0.4%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Anaemia 0.5%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Vomiting 0.6%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Neutropenia 1%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Febrile neutropenia 1.5%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.130
Alkaline phosphatase increased grade 3, 0.4%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
AST increased grade 3, 0.8%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
ALT increased grade 3, 1.3%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
Hypokalemia grade 3, 1.4%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
Hyponatremia grade 3, 4.9%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
Hyperglycemia grade 3, 7.8%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
AST increased grade 4, 0.1%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
Hypokalemia grade 4, 0.4%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
Hyperglycemia grade 4, 0.6%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
Hyponatremia grade 4, 0.6%
300 mg 1 times / 5 weeks multiple, oral
Recommended
Dose: 300 mg, 1 times / 5 weeks
Route: oral
Route: multiple
Dose: 300 mg, 1 times / 5 weeks
Co-administed with::
palonosetron(0.5 mg; prior to the start of chemotherapy cycle)
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
unhealthy, median age 55 years
n = 1033
Health Status: unhealthy
Condition: cancer
Age Group: median age 55 years
Sex: M+F
Population Size: 1033
Sources: Page: assessment-report/akynzeo-epar-public-assessment-report_en.pdf - p.135
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
weak [IC50 22.6 uM]
weak [IC50 23.73 uM]
weak [IC50 26.41 uM]
weak [IC50 33.26 uM]
weak [IC50 38.84 uM]
weak [IC50 39.04 uM]
weak [IC50 39.39 uM]
weak [IC50 57.45 uM]
weak [IC50 6 uM]
weak [IC50 8.6 uM]
weak
weak
yes [IC50 1.2 uM]
yes [IC50 19 uM]
yes [IC50 22.3 uM]
yes [IC50 22.6 uM]
yes [IC50 33.38 uM]
yes [IC50 4.74 uM]
yes [IC50 4.89 uM]
yes [IC50 4.95 uM]
yes [IC50 50.4 uM]
yes [IC50 7.4 uM]
yes [IC50 7.9 uM]
yes [IC50 8 uM]
yes [IC50 8.54 uM]
yes [Ki 1.1 uM]
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
yes
yes
yes
yes
yes (co-administration study)
Comment: Administration of the CYP3A4 inhibitor ketoconazole with netupitant/palonosetron FDC increased the exposure of netupitant and resulted in an AUC0-tz of 1.8 fold, AUC0-’ of 2.4 fold, and Cmax of 1.3 fold when compared to the administration of netupitant/palonosetron FDC alone.
Page: 73.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.
2006 Apr 1
Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.
2006 Mar 1
Efficient synthesis of novel NK1 receptor antagonists: selective 1,4-addition of grignard reagents to 6-chloronicotinic acid derivatives.
2006 Mar 3
Patents

Sample Use Guides

One AKYNZEO (netupitant and palonosetron) capsule administered approximately 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy on day 1 and 8 mg orally once daily on days 2 to 4 (for highly emetogenic chemotherapy, including cisplatin based chemotherapy) or on day 1 with not necessary administration of dexamethasone on days 2 to 4 (for anthracyclines and cyclophosphamide based chemotherapy and chemotherapy not considered highly emetogenic)
Route of Administration: Oral
In Vitro Use Guide
HEK-293 cells were incubated with 5 nM [3H]-netupitant for 40 min at room temperature.
Substance Class Chemical
Created
by admin
on Sat Jun 26 01:07:34 UTC 2021
Edited
by admin
on Sat Jun 26 01:07:34 UTC 2021
Record UNII
7732P08TIR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NETUPITANT
DASH   INN   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
NETUPITANT COMPONENT AKYNZEO CAPSULE
Brand Name English
NETUPITANT [USAN]
Common Name English
NETUPITANT [ORANGE BOOK]
Common Name English
NETUPITANT [WHO-DD]
Common Name English
NETUPITANT [INN]
Common Name English
AKYNZEO CAPSULE COMPONENT NETUPITANT
Brand Name English
RO-67-3189/000
Code English
BENZENEACETAMIDE, N,.ALPHA.,.ALPHA.-TRIMETHYL-N-(4-(2-METHYLPHENYL)-6-(4-METHYL-1-PIPERAZINYL)-3-PYRIDINYL)-3,5-BIS(TRIFLUOROMETHYL)-
Systematic Name English
RO 67-3189/000
Code English
2-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)-N,2-DIMETHYL-N-(4-(2-METHYLPHENYL)-6-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)PROPANAMIDE
Systematic Name English
RO-673189000
Code English
NETUPITANT [VANDF]
Common Name English
NETUPITANT [MI]
Common Name English
RO-67-3189
Code English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS AKYNZEO (AUTHORIZED: NAUSEA)
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
NDF-RT N0000175786
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
NCI_THESAURUS C267
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
Code System Code Type Description
PUBCHEM
6451149
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
INN
8409
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
FDA UNII
7732P08TIR
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
ChEMBL
CHEMBL206253
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
NDF-RT
N0000190113
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
CAS
290297-26-6
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
DRUG CENTRAL
4898
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
NDF-RT
N0000182141
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
NDF-RT
N0000185503
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY P-Glycoprotein Inhibitors [MoA]
EVMPD
SUB130488
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
EPA CompTox
290297-26-6
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
IUPHAR
5742
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
DRUG BANK
DB09048
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
NCI_THESAURUS
C96745
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
MESH
C508854
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
RXCUI
1552337
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY RxNorm
MERCK INDEX
M11791
Created by admin on Sat Jun 26 01:07:35 UTC 2021 , Edited by admin on Sat Jun 26 01:07:35 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
Netupitnat: Cmax/IC50= (1-1.5μM)/6 μM = (0.167-0.25)>0.1
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
METABOLITE ACTIVE -> PARENT
of parent exposure
MAJOR
AUC
METABOLITE ACTIVE -> PARENT
of parent exposure
MAJOR
AUC
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
ACTIVE MOIETY